Selective GRK5 Inhibitor Compounds for Disease-Specific Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for heart disease and cancer fail to address the challenges of heart disease and cancer fail to address the challenges of heart disease and cancer fail to address the challenges of heart disease and cancer.

Innovation Solution

The compounds are demonstrably selective and potent inhibitors of G protein-coupled receptor kinase 5 (GRK5).

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used for heart disease and cancer, then current standard therapies are administered, but they fail to address the specific challenges of these diseases effectively

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddisease-specific targeting

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs parameter changes by developing compounds with specific molecular structures (formula I) that selectively bind to GRK5 with different inhibition constants (Ki values). The chemical parameters such as substituent groups (R1-R9) are optimized to achieve selective inhibition of GRK5 over other GRK isoforms, thereby improving treatment effectiveness for GRK5-mediated diseases while maintaining adaptability through structure-activity relationship optimization.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by designing inhibitors with specific functional groups and structural features at particular positions within the molecule. The substituent patterns at R1, R2, R3, and other positions are locally optimized to interact with specific residues in the GRK5 active site, enabling selective inhibition of GRK5 while sparing other kinase isoforms, thus achieving disease-specific targeting.

Inventive Principle:

Principle #3Local quality

2Reliability

If selective GRK5 inhibitors are developed, then treatment specificity for GRK5-mediated diseases is improved, but the complexity of drug development and characterization increases

Engineering Contradiction:

ImproveselectivityVSAvoidinhibitor characterization

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the GRK5 inhibition assessment into multiple discrete components: (1) determination of IC50 values in enzyme assays, (2) measurement of Ki values for different GRK isoforms (GRK2, GRK3, GRK4, GRK5, GRK6), and (3) evaluation of selectivity ratios. This segmented approach to characterization systematically manages the complexity of proving selectivity while providing comprehensive data on inhibitor properties.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses intermediary assays and surrogate markers to simplify the characterization process. By employing radiometric kinase assays with labeled substrates and using cell-based functional assays as intermediaries between in vitro enzyme inhibition and in vivo efficacy, the complex process of characterizing selective GRK5 inhibitors is broken into manageable steps that can be performed with standardized protocols.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250388567A1Selective g protein-coupled receptor kinase 5 inhibitors, compositions, and methods of use

Publication Date: 2025.12.25 PURDUE RES FOUND

AI summary

Highly selective and potent inhibitors of G protein-coupled receptor kinase 5 (GRK5), a pharmaceutical composition comprising same, and a method of use, such as in the treatment of heart disease or cancer.